Wilson Sonsini Goodrich & Rosati advised Arcellx on the deal. Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series...
Arcellx’s $115 Million Series C Financing
Vividion Therapeutics’ $135 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal. Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies...